CEL-SCI completes key milestone with clearance to conduct phase III trial in 21 countries
CEL-SCI announced the Ministry of Health of the Republic of Belarus has cleared the Company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine. Belarus is the 21th country to approve CEL-SCI's Phase III trial. February 27, 2015